26.79
0.02 (0.07%)
| Previous Close | 26.77 |
| Open | 26.78 |
| Volume | 1,543,306 |
| Avg. Volume (3M) | 3,168,638 |
| Market Cap | 1,426,323,456 |
| Price / Earnings (Forward) | 25.45 |
| Price / Sales | 974.52 |
| Price / Book | 49.03 |
| 52 Weeks Range | |
| Earnings Date | 13 Aug 2026 |
| Diluted EPS (TTM) | -3.69 |
| Total Debt/Equity (MRQ) | 3.98% |
| Current Ratio (MRQ) | 10.44 |
| Operating Cash Flow (TTM) | -127.65 M |
| Levered Free Cash Flow (TTM) | -72.82 M |
| Return on Assets (TTM) | -58.15% |
| Return on Equity (TTM) | -150.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | KalVista Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.47% |
| % Held by Institutions | 112.39% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |